Home » News » Awards & Advancement » GeoVax receives $3.6 million grant for HIV/AIDS vaccine program

GeoVax receives $3.6 million grant for HIV/AIDS vaccine program

Tuesday, August 16, 2011

GeoVax Labs, a biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, has received a $3.6 million annual notice of award for the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Grant supporting GeoVax’s HIV/AIDS vaccine program.

This grant was originally awarded in 2007 to GeoVax by the National Institutes of Health-National Institute of Allergy & Infectious Disease (NIH-NIAID), an agency of the U.S. Government.  Only meritorious HIV/AIDS prevention vaccine candidates are considered to receive an IPCAVD award.

GeoVax will utilize this funding to further production of its GM-CSF adjuvanted vaccine for planned human clinical trials.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!